BD's Three Consecutive Quarters of Losses Suggest the Turnaround Timeline Has Shifted

Becton, Dickinson and Company (BDX) reports fiscal Q3 2026 earnings before the market opens on August 6, 2026. With analysts expecting a sharp 14.67% year-over-year decline in earnings, the central question is whether the medical technology giant can stabilize its performance after a challenging period. The stock has rallied significantly heading into the release, trading at $170.66 and sitting above all key moving averages, setting up a critical test of whether recent momentum can withstand what appears to be a difficult earnings comparison.

Part 1: Earnings Preview

Becton, Dickinson and Company is a global medical technology company that develops, manufactures, and sells medical devices, instrument systems, and reagents across three core segments: BD Medical, BD Life Sciences, and BD Interventional. The company serves healthcare institutions, physicians, life science researchers, clinical laboratories, and the pharmaceutical industry worldwide.

BDX is scheduled to report fiscal Q3 2026 results before the market opens on August 6, 2026. Analysts expect earnings per share of $3.14 on revenue of $4.89 billion. The company most recently reported Q2 2026 earnings of $2.90 per share, which beat estimates by 4.69%. However, the upcoming quarter faces a tough year-over-year comparison: the $3.14 consensus represents a 14.67% decline from the $3.68 reported in Q3 2025, while revenue is projected to fall 11.2% from the prior-year period.

Three key themes define this earnings story:

1. Post-Divestiture Performance: BDX recently completed the sale of its diabetes care business to focus on core medical technology operations. Investors will scrutinize whether the streamlined business model is delivering improved margins and operational efficiency, or if the revenue headwind from the divestiture is masking underlying weakness in remaining segments.

2. GLP-1 Therapy Positioning: The company announced a strategic partnership in Brazil for semaglutide therapy delivery, positioning BDX to capitalize on the explosive growth in weight-loss and diabetes medications. The earnings call will likely address how the company plans to leverage its injection device portfolio to capture share in this high-growth market.

3. Capital Allocation Strategy: With proceeds from the Waters business sale, management has signaled plans for share buybacks. Investors want clarity on the pace and magnitude of repurchases, as well as the balance between returning cash to shareholders and investing in organic growth initiatives.

Analyst commentary ahead of the release reflects cautious optimism. While the year-over-year comparison is challenging due to the divestiture, several analysts note that the company's core medical device segments are showing resilience. The recent dividend declaration of $1.05 per share signals management confidence in cash flow generation despite near-term earnings pressure.

Part 2: Historical Earnings Performance

BDX has demonstrated consistent execution over the past four quarters, beating earnings estimates in every report. The company delivered a 7.60% beat in Q3 2025 ($3.68 actual vs. $3.42 estimate), followed by a 1.02% beat in Q4 2025, a 3.19% beat in Q1 2026, and most recently a 4.69% beat in Q2 2026.

The pattern reveals a company that has reliably exceeded Wall Street expectations, though the magnitude of beats has varied. The largest surprise came in Q3 2025, while the most recent quarters have shown more modest but still positive surprises in the 3-5% range. This track record suggests management has maintained conservative guidance and operational discipline, consistently delivering results that edge past consensus forecasts.

Heading into Q3 2026, this history of beats provides some cushion against the challenging year-over-year comparison. However, investors should note that all four recent beats occurred against estimates that were themselves declining, reflecting the broader headwinds facing the business.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

BDX reports before the market opens, meaning Day 0 captures the first full trading session reaction to results, while Day +1 reflects follow-through momentum.

Historical price action around BDX earnings shows significant volatility, with an average absolute Day 0 move of 5.41% and Day +1 move of 2.92%. The most dramatic reaction came in May 2025, when the stock plunged 18.13% on earnings day, though that appears to be an outlier. More typically, the stock has moved 3-9% on earnings day, with direction varying widely—recent reports have triggered moves ranging from an 8.86% surge (August 2025) to a 5.39% decline (November 2024).

The Day +1 follow-through has been more muted but still meaningful at 2.92% on average, suggesting initial reactions often extend into the next session. Intraday volatility is also notable, with Day 0 trading ranges averaging 5.33% and Day +1 ranges averaging 4.01%, indicating substantial price discovery occurs in the sessions immediately following results.

Part 2.2: Options Market Expected Move

The options market is pricing a 6.30% expected move ($10.71) for the August 21 expiration, which is slightly above the historical average Day 0 move of 5.41% but well within the range of recent earnings reactions. This suggests options traders are anticipating elevated volatility consistent with BDX's recent earnings history, though not expecting an outlier move like the May 2025 decline.

Part 3: What Analysts Are Saying

Analysts maintain a moderately bullish stance on BDX heading into earnings, with a consensus rating of 3.88 out of 5.0 (between Hold and Buy). The analyst community includes 7 Strong Buy ratings and 9 Hold ratings, with no Sell or Strong Sell recommendations among the 16 analysts covering the stock. The average price target of $176.00 implies 3.1% upside from the current price of $170.66, with a range spanning from $152.00 to $204.00.

Sentiment has improved over the past month, with Strong Buy ratings increasing from 6 to 7. This modest upgrade suggests growing confidence among analysts as the earnings date approaches, despite the challenging year-over-year comparison. The relatively tight clustering of ratings around Hold and Strong Buy—with no bearish calls—indicates consensus that BDX's fundamental business remains solid even as it navigates the post-divestiture transition.

The price target range reveals some divergence in views on valuation. The high estimate of $204.00 implies nearly 20% upside and likely reflects optimism about the company's positioning in high-growth markets like GLP-1 delivery systems. The low estimate of $152.00 sits below the current price, suggesting at least one analyst sees limited near-term upside given the earnings headwinds.

Part 4: Technical Picture

BDX enters earnings with strong technical momentum, as the Barchart Technical Opinion currently stands at 56% Buy, up sharply from 40% Buy one week ago and 8% Buy one month ago. This rapid improvement in the signal reflects the stock's powerful rally heading into the release, with shares climbing above all major moving averages.

Timeframe Analysis:

• Short-term (100% Buy): Maximum bullish signal indicates powerful near-term momentum as the stock surges into earnings
• Medium-term (Hold): Neutral reading suggests the intermediate trend is consolidating after the recent advance
• Long-term (50% Buy): Moderate buy signal reflects improving but not yet fully established strength in the longer-term trend

Trend Characteristics: The technical setup shows Average strength but is Strengthening, indicating momentum is building but has not yet reached extreme overbought conditions that might limit further upside.

The stock is trading at $170.66, positioned above all key moving averages: the 5-day ($168.41), 10-day ($164.51), 20-day ($159.34), 50-day ($153.05), 100-day ($152.77), and 200-day ($155.40). This alignment with the stock above every major average is a classically bullish technical setup, though it also means there is significant air underneath current levels if earnings disappoint.

The 52-week range of $127.59 to $187.35 shows BDX has recovered substantially from its lows but remains about 9% below its recent peak. Key support now sits at the 20-day moving average around $159, which would represent a roughly 7% pullback—well within the historical Day 0 move range. The overall technical setup is supportive heading into earnings, with strong momentum and improving breadth, but the extended rally also means the stock has less cushion to absorb a disappointment. Investors should be prepared for volatility consistent with the 6.30% expected move, with the 50-day average around $153 serving as a critical support zone if results or guidance fall short.